نتایج جستجو برای: modifying drugs

تعداد نتایج: 257803  

Journal: :Open journal of rheumatology and autoimmune diseases 2012
Julia F Simard Murray A Mittleman Nancy A Shadick Elizabeth W Karlson

BACKGROUND Anti-TNF treatment may increase infection risk, although this has been difficult to study because the timing of anti-TNF treatment is driven by disease activity, which may influence infection susceptibility leading to confounding that varies over time. We evaluated the association between anti-TNF initiation in rheumatoid arthritis (RA) patients on disease modifying anti-rheumatic dr...

Journal: :Nutrition research reviews 2009
Kurt M Reinhart Ripple Talati C Michael White Craig I Coleman

In order to determine the impact of garlic on total cholesterol (TC), TAG levels, as well as LDL and HDL, and establish if any variables have an impact on the magnitude of this effect, a meta-analysis was conducted. A systematic literature search of MEDLINE, CINAHL and the Cochrane Database from the earliest possible date through to November 2007 was conducted to identify randomised, placebo-co...

2015
González-Álvaro I Ortiz A.M Seoane I.V García-Vicuña R Martínez C Gomariz R.P

The heterogeneous nature of rheumatoid arthritis (RA) complicates early recognition and treatment. In recent years, a growing body of evidence has demonstrated that intervention during the window of opportunity can improve the response to treatment and slow- or even stop-irreversible structural changes. Advances in therapy, such as biologic agents, and changing approaches to the disease, such a...

2017
Lucía Silva Fernández Mónica Fernández Castro José Luis Andreu Sánchez

Use of glucocorticoids (GC) began more than 50 years ago for the treatment of rheumatoid arthritis (RA). However, up until a decade ago, its potential role as a disease modifying anti-rheumatic drug (DMARD) and its capacity to prevent radiologic damage had not been proposed. Some initial studies indicated a disease modifying drug, but in the following years, probably due to questions regarding ...

Journal: :Arthritis Research & Therapy 2006
Klaus P Machold Valerie PK Nell Tanja A Stamm Josef S Smolen

There is increasing evidence for beneficial effects of early DMARD (disease-modifying antirheumatic drug) therapy over delayed treatment in patients who present with arthritis of recent onset. However, no universal consensus exists concerning the choice of initial drug or whether single drugs or combinations should be given as initial treatments. Recent studies have focused on the benefits of v...

2016
Juergen Rech Axel J Hueber Stephanie Finzel Matthias Englbrecht Judith Haschka Bernhard Manger Arnd Kleyer Michaela Reiser Jayme Fogagnolo Cobra Camille Figueiredo Hans-Peter Tony Stefan Kleinert Joerg Wendler Florian Schuch Monika Ronneberger Martin Feuchtenberger Martin Fleck Karin Manger Wolfgang Ochs Matthias Schmitt-Haendle Hanns-Martin Lorenz Hubert Nuesslein Rieke Alten Joerg Henes Klaus Krueger Georg Schett

OBJECTIVE To analyse the role of multibiomarker disease activity (MBDA) score in predicting disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who tapered disease modifying antirheumatic drug (DMARD) therapy in RETRO, a prospective randomised controlled trial. METHODS MBDA scores (scale 1-100) were determined based on 12 inflammation markers in baseline serum s...

2012
Javier Rueda-Gotor Miguel A González-Gay Ricardo Blanco

Tocilizumab (TCZ) is a humanized monoclonal antibody against the IL‐6 receptor, approved in Japan, Europe and the USA for the treatment of severe rheumatoid arthritis. Several Phase III trials have shown a clinical efficacy of TCZ, such as in treatment of rheumatoid arthritis patients with no previous methotrexate failures both in combination with methotrexate and in monotherapy (the AMBITION t...

Journal: :Clinical and experimental rheumatology 2003
B Svensson M Ahlmén K Forslind

OBJECTIVES To study the outcome in clinical practice of first DMARD and/or corticosteroid (CS) treatment in patients with recent onset rheumatoid arthritis (RA). PATIENTS 245 patients with active RA, not previously treated with DMARDs or CS, were randomised to one of two treatment groups, T1 = 7.5-15 mg of prednisolone (PRE) daily for one to three months followed, if needed, by methotrexate (...

2005
A Zink J Kekow M Schneider R Rau

A Zink, J Listing, S Kary, P Ramlau, M Stoyanova-Scholz, K Babinsky, U von Hinueber, E Gromnica-Ihle, S Wassenberg, C Antoni, P Herzer, J Kekow, M Schneider, R Rau . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....

Journal: :Clinical and experimental rheumatology 2013
Kazuki Yoshida Helga Radner Arthur Kavanaugh Yoon-Kyoung Sung Sang-Cheol Bae Mitsumasa Kishimoto Kazuo Matsui Masato Okada Shigeto Tohma Michael E Weinblatt Daniel H Solomon

Many studies have been conducted concerning discontinuation of biologic disease-modifying anti-rheumatic drugs (DMARD), but mainly in trial settings which result in limited generalisability. Registry studies can complement the current literature of biologic DMARD discontinuation by providing more generalisable information. However, it may be necessary to combine registries to increase power and...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید